期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

靶向于受体酪氨酸激酶的胃癌分子靶向治疗 被引量：2

Molecular targeted therapies:targeting receptor tyrosine kinases in the treatment of gastric cancer
下载PDF
导出
摘要 胃癌是一种常见的高死亡率的疾病,相当一部分患者确诊时已经处于晚期,失去手术时机,而胃癌对于细胞毒类抗肿瘤药物、放疗又不甚敏感。研究发现酪氨酸激酶的突变激活和/或过度表达可使细胞发生转变,在肿瘤形成中起重要的作用。本文主要对以酪氨酸激酶为靶点的生物靶向药物在胃癌治疗中的研究进展进行概述,主要可以归纳为三个方面:①以ErbB通道为靶点的靶向治疗;②以血管内皮生长因子(VEGF)及其受体通道为靶点的靶向治疗;③以其他受体如胰岛素样生长因子-1受体(IGF1R)为靶点的靶向治疗。 Gastric cancer is a common disease with high mortality.Apart from potentially curative surgery,chemotherapy as well as radiochemotherapy may be applied,but the efficacy is unsatisfactory.Receptor tyrosine kinases(RTKs) participate in several steps of tumor formation,and also become new targets for a selective therapy in gastric cancer.In this review,a brief introduction of the current status about the receptor tyrosine kinases(RTKs) of the molecular targeted therapies in the treatment of gastric cancer and ...
作者 林晓琳 程时丹 慎睿哲 王立夫
机构地区 上海交通大学医学院附属瑞金医院消化内科
出处 《胃肠病学和肝病学杂志》 CAS 2009年第11期974-979,共6页 Chinese Journal of Gastroenterology and Hepatology
关键词 胃癌 靶向治疗 受体酪氨酸激酶 EGFR抑制剂 VEGF抑制剂 Gastric cancer Targeted therapy Receptor tyrosine kinases EGFR inhibitor VEGF inhibitor
分类号 R735.2 [医药卫生—肿瘤]
  • 相关文献

参考文献6

  • 1曹卫国,马韬,李建芳,黎皓,纪玉宝,陈雪华,刘炳亚,金冶宁.吉非替尼对胃癌细胞株放射增敏的作用[J].癌症,2007,26(12):1330-1335. 被引量：14
  • 2蒋晓婷,陶厚权,邹寿椿.血管生成抑制剂SU6668对SCID鼠胃癌生长和转移抑制的作用[J].中华胃肠外科杂志,2006,9(4):335-337. 被引量：12
  • 3Kaori Fujimoto-Ouchi,Fumiko Sekiguchi,Hideyuki Yasuno,Yoichiro Moriya,Kazushige Mori,Yutaka Tanaka. Antitumor activity of trastuzumab in combination with chemotherapy in human gastric cancer xenograft models[J] 2007,Cancer Chemotherapy and Pharmacology(6):795～805
  • 4Dong Il Park,Jung Won Yun,Jung Ho Park,Suk Joong Oh,Hong Joo Kim,Yong Kyun Cho,Chong Il Sohn,Woo Kyu Jeon,Byung Ik Kim,Chang Hak Yoo,Byung Ho Son,Eun Yoon Cho,Seoung Wan Chae,Eo-Jin Kim,Jin Hee Sohn,Seung Ho Ryu,Antonia R. Sepulveda. HER-2/neu Amplification Is an Independent Prognostic Factor in Gastric Cancer[J] 2006,Digestive Diseases and Sciences(8):1371～1379
  • 5Yixing Jiang,Liwei Wang,Weida Gong,Daoyan Wei,Xiangdong Le,James Yao,Jaffer Ajani,James L. Abbruzzese,Suyun Huang,Keping Xie. A high expression level of insulin-like growth factor I receptor is associated with increased expression of transcription factor Sp1 and regional lymph node metastasis of human gastric cancer[J] 2005,Clinical & Experimental Metastasis(8):755～764
  • 6Osamu Kishida,Yoshiji Miyazaki,Yoko Murayama,Miyuki Ogasa,Tamana Miyazaki,Takahiro Yamamoto,Kenji Watabe,Shusaku Tsutsui,Tatsuya Kiyohara,Iichiro Shimomura,Yasuhisa Shinomura. Gefitinib (Iressa, ZD1839) inhibits SN38-triggered EGF signals and IL-8 production in gastric cancer cells[J] 2005,Cancer Chemotherapy and Pharmacology(6):584～594

二级参考文献17

  • 1王明国,王中和,胡海生.表皮生长因子受体抗体对人舌鳞癌细胞增殖和放射敏感性的影响[J].中华放射肿瘤学杂志,2004,13(4):334-334. 被引量：7
  • 2Laird AD,Christensen JG,Li G,et al.SU6668 inhibits Flk-1/KDR and PDGFR beta in vivo,resulting in rapid apoptosis of tumor vasculature and tumor regression in mice.FASEB J,2002,16:681-690.
  • 3Weidner N,Folkman J,Pozza F,et al.Tumor angiogenesis.A new significant and independent prognostic factor in early-stage breast carcinoma.J Natl Cancer Inst,1992,84:1875-1887.
  • 4Xiong HQ,Herbst R,Faria SC,et al.A phase Ⅰ surrogate endpoint study of SU6668 in patients with solid tumors.Invest New Drugs,2004,2:459-466.
  • 5Garofalo A,Naumova E,Manenti L,et al.The combination of the tyrosine kinase receptor inhibitor SU6668 with paclitaxel affects ascites formation and tumor spread in ovarian carcinoma xenografts growing orthotopically.Clin Cancer Res,2003,9:3476-3485.
  • 6Laird AD,Vajkoczy P,Shawver LK,et al.SU6668 is a potent antiangiogenic and antitumor agent that induces regression of established tumors.Cancer Res,2000,60:4152-4160.
  • 7Marzola P,Degrassi A,Calderan L,et al.In vivo assessment of antiangiogenic activity of SU6668 in an experimental colon carcinoma model.Clin Cancer Res,2004,10:739-750.
  • 8Macdonald J S, Smalley S R, Benedetti J, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction [J]. N Engl J Med, 2001,345(10):725-730.
  • 9刘桂芬.半数效量[M]//蒋知俭.医学统计学.北京:人民卫生出版社,1997:136-153.
  • 10Herbst R S, Langer C J. Epidermal growth factor receptors as atarget for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancers [J]. Semin Oncol, 2002,29(Suppl 4) : 27-36.

共引文献24

同被引文献29

  • 1蒋晓婷,陶厚权,邹寿椿.血管生成抑制剂SU6668对SCID鼠胃癌生长和转移抑制的作用[J].中华胃肠外科杂志,2006,9(4):335-337. 被引量：12
  • 2龚新雷,秦叔逵.卡培他滨治疗进展期胃癌的临床及实验研究进展[J].临床肿瘤学杂志,2007,12(9):708-713. 被引量：34
  • 3Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitin ib ( Iressa, ZD1839) in non -small cell lung cancer cell lines correlates with de- pendence on the epidermal growth factor (EGF) receptor/extraeellular signal regulated kinase 1/2 and EGF receptor/Akt pathway for prolifer- ation [ J 1. Mol Cancer Ther,2004,3 (4) :465 - 472.
  • 4Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer [ J 1. Crit Rev Oncol Hematol, 2003,47 (2) :195 -206.
  • 5Bellmunt J, Hussain M, Dinney CP. Novel approaches with targetedtherapies in bladder cancer. Therapy of bladder cancer by blockade of the epidermal growth factor receptor family[ J]. Crit Rev Oncol Hema- tol, 2003,46(Suppl) :85 - 104.
  • 6Perrotte P, Matsumoto T, Inoue K, et al. Anti epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice [ J ]. Clin Cancer Res, 1999,5 (2) :257 - 265.
  • 7Inoue K, Slaton JW, Perrotte P, et al. Paclitaxel enhances the effects of the anti epidermal growth factor receptor monoelonal antibody Im - Clone C225 in mice with metastatic human bladder transitional cell carcinoma [ J]. Clin Cancer Res ,2000,6 ( 12 ) :4874 - 4884.
  • 8Mendelsohn J, Baselga J. Status of epidermal growth factor receptor an- tagonists in the biology and treatment of cancer[ J]. J Clin Oncol,2003, 21 (14) :2787 -2799.
  • 9Herbst RS. ZD1839:targeting the epidermal growth factor receptor in cancer therapy[ J ]. Expert Op in Invest Drugs, 2002,11:837 - 849.
  • 10Huang s, Armstrong EA, Benavente s, el al. Dualagent molecular targe- ting of the epidermal growth factor receptor(EGFR) :combining anti - EGFR antibody with tyrosine kinase inhibitor[J]. Cancer Res,2004,64 ( 15 ) :5355 - 5362.

引证文献2

二级引证文献11

胃肠病学和肝病学杂志
2009年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部